Trial Profile
A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 May 2019
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Defactinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Verastem Oncology
- 28 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.